AIO-Studien-gGmbH — CureCurrent

How to interpret these research links

Connected source records

The exact organization name AIO-Studien-gGmbH appears in 16 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials16

Recruiting shown2

Roles1

SourceClinicalTrials.gov

Clinical trials

16 shown

Study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor Performance StatusNCT07803848 · lead sponsor · 2025-01-01

Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma PatientsNCT02622581 · lead sponsor · 2015-12-01

Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer With a High Tumor BurdenNCT07715396 · lead sponsor · 2026-10-30

NOT_YET_RECRUITING

Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)NCT05383001 · lead sponsor · 2022-05-20

Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort StudyNCT05089916 · lead sponsor · 2022-01-20

ACTIVE_NOT_RECRUITING

Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-EtoposideNCT04221529 · lead sponsor · 2020-01-06

Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung CancerNCT03197467 · lead sponsor · 2018-06-18

Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma HistologyNCT04046614 · lead sponsor · 2018-05-25

Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)NCT03345810 · lead sponsor · 2017-12-14

Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLCNCT03044626 · lead sponsor · 2017-02-10

Study of Pembrolizumab Maintenance Following First-Line Platinum Based Chemotherapy in Patients With Metastatic Squamous - Non-Small Cell Lung Cancer (sNSCLC)NCT02564380 · lead sponsor · 2016-01-19

Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIBNCT02326285 · lead sponsor · 2015-11-01

Maintaining ERBB Blockade in EGFR-mutated Lung CancerNCT02488694 · lead sponsor · 2015-11-01

A Study of Cabazitaxel for Patients With Breast or Lung Cancer and Recurrent or Progressive Brain Metastases - Cabazitaxel for Brain Metastases (CaBaMet)NCT02166658 · lead sponsor · 2015-08-01

Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast CancerNCT01520103 · lead sponsor · 2012-01-01

A Randomized, Open-label Phase III Trial of Mapisal® Versus an Urea Hand-foot Cream as Prophylaxis for Capecitabine-induced Hand-foot Syndrome in Patients With Gastrointestinal Tumors or Breast CancerNCT01626781 · lead sponsor

NO_LONGER_AVAILABLE

Sponsor roles

lead sponsor16

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.